A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor
| Autor: | B. khoeiny, R. Fayazfar, Gh. Toogeh, Mohammad Faranoush, Mehran Karimi, Hassan Abolghasemi, K. Kamyar, B. Keikhaei Dehdezi, Majid Naderi, N B Mirbehbahani, Hamid Hoorfar, Peyman Eshghi, M. R. Baghaeipour, Fereidoun Mahboudi, R. Heshmat, Mohammadreza Managhchi, Minoo Ahmadinejad, B. Vaziri, Azim Mehrvar |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Time Factors Adolescent Hemorrhage Factor VIIa 030204 cardiovascular system & hematology Pharmacology Hemophilia A law.invention 03 medical and health sciences 0302 clinical medicine Biosimilar Pharmaceuticals law Activated factor VII Blood Coagulation Factor Inhibitors Medicine Humans In patient Child Bleeding episodes business.industry Hematology General Medicine Recombinant Proteins 030220 oncology & carcinogenesis Recombinant DNA Female business |
| Zdroj: | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 22(2) |
| ISSN: | 1938-2723 |
| Popis: | Introduction: This study compared the efficacy of Aryoseven with Novoseven to control bleeding episodes in patients with hemophilia A with inhibitors. Methods: Sixty-six patients were randomized into 2 groups, with 4 consecutive block randomization. These groups received Aryoseven and Novoseven dosages of 90 to 120 μg/kg intravenously every 2 hours. Results: Median (interquartile range) level of factor VIII (FVIII) inhibitor in groups A and B was 15.0 and 19.0 Bethesda Unit (BU) preadministration. Bleeding onset in group A was 1246 ± 1104 minutes and in group B was 2301 ± 1693 minutes ( P = .311). The Kavakli global response scores and treatment success rate was comparable in both the groups. The side effects in groups A (9.7%) and B (2.9%) were comparable. Conclusion: Biosimilar recombinant activated FVII is found to be as effective as Novoseven in the treatment of acute joint bleeding in patients with hemophilia with inhibitors. Its usage will decrease the gaps in hemophilia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|